IP Library › Granted Patent US 10,822,295
Granted Patent B2
US 10,822,295 · App. 16/563,099 · Granted Nov 3, 2020

Menaquinol compositions and methods of treatment

Inventors: Keith E. Drouet (San Diego, CA); James A. Tumlin (Suford, PA)
Assignee: EPIZON PHARMA, INC.
C07C46/10A61P1/16C07C37/00C07C67/03C07D405/06C07B2200/13C07C39/225C07C50/14C07C69/017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,822,295
App. No.
16/563,099
Granted
Nov 3, 2020
Kind
B2
Abstract

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a menaquinol compound as disclosed above, or a mixture thereof, and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K selected from for the treatment of osteoporosis and arteriosclerosis.

Claims (73)

1. A menaquinol compound of the Formula I:

wherein:

m is 7, 8, 9 or 10;

R 1 and R 2 are both the residue 15;

R 1 and R 2 are both the residue 16;

R 1 and R 2 are both the residue 17;

R 1 and R 2 are both the residue 18;

R 1 and R 2 are both the residue 20;

R 1 and R 2 are both the residue 21;

R 1 and R 2 are both the residue 22;

R 1 and R 2 are both the residue 23;

R 1 and R 2 are both the residue 24;

R 1 and R 2 are both the residue 25;

R 1 and R 2 are both the residue 26;

R 1 and R 2 are both the residue 27;

R 1 and R 2 are both the residue 28;

R 1 is H and R 2 is the residue 15; R 2 is H and R 1 is the residue 15;

R 1 is H and R 2 is the residue 16; R 2 is H and R 1 is the residue 16;

R 1 is H and R 2 is the residue 17; R 2 is H and R 1 is the residue 17;

R 1 is H and R 2 is the residue 18; R 2 is H and R 1 is the residue 18;

R 1 is H and R 2 is the residue 20; R 2 is H and R 1 is the residue 20;

R 1 is H and R 2 is the residue 21; R 2 is H and R 1 is the residue 21;

R 1 is H and R 2 is the residue 22; R 2 is H and R 1 is the residue 22;

R 1 is H and R 2 is the residue 23; R 2 is H and R 1 is the residue 23;

R 1 is H and R 2 is the residue 24; R 2 is H and R 1 is the residue 24;

R 1 is H and R 2 is the residue 25; R 2 is H and R 1 is the residue 25;

R 1 is H and R 2 is the residue 26; R 2 is H and R 1 is the residue 26;

R 1 is H and R 2 is the residue 27; R 2 is H and R 1 is the residue 27; and

R 1 is H and R 2 is the residue 28; R 2 is H and R 1 is the residue 28;

2. The compound of claim 1 of the Formula I, wherein:

R 1 and R 2 are both the residue 15;

R 1 and R 2 are both the residue 16;

R 1 and R 2 are both the residue 17;

R 1 and R 2 are both the residue 18;

R 1 and R 2 are both the residue 20;

R 1 and R 2 are both the residue 21;

R 1 and R 2 are both the residue 22;

R 1 and R 2 are both the residue 23;

R 1 and R 2 are both the residue 24;

R 1 and R 2 are both the residue 25;

R 1 and R 2 are both the residue 26;

R 1 and R 2 are both the residue 27; and

R 1 and R 2 are both the residue 28.

3. The compound of claim 1 of the Formula I, wherein:

R 1 is H and R 2 is the residue 15; R 2 is H and R 1 is the residue 15;

R 1 is H and R 2 is the residue 16; R 2 is H and R 1 is the residue 16;

R 1 is H and R 2 is the residue 17; R 2 is H and R 1 is the residue 17;

R 1 is H and R 2 is the residue 18; R 2 is H and R 1 is the residue 18;

R 1 is H and R 2 is the residue 20; R 2 is H and R 1 is the residue 20;

R 1 is H and R 2 is the residue 21; R 2 is H and R 1 is the residue 21;

R 1 is H and R 2 is the residue 22; R 2 is H and R 1 is the residue 22;

R 1 is H and R 2 is the residue 23; R 2 is H and R 1 is the residue 23;

R 1 is H and R 2 is the residue 24; R 2 is H and R 1 is the residue 24;

R 1 is H and R 2 is the residue 25; R 2 is H and R 1 is the residue 25;

R 1 is H and R 2 is the residue 26; R 2 is H and R 1 is the residue 26;

R 1 is H and R 2 is the residue 27; R 2 is H and R 1 is the residue 27; and

R 1 is H and R 2 is the residue 28; R 2 is H and R 1 is the residue 28.

4. The menaquinol compound of the Formula I of claim 1 , wherein

m is 7, 8, 9 or 10;

R 1 is H and R 2 is the acyl residue of caffeic acid 20: or

R 2 is H and R 1 is the acyl residue of caffeic acid 20;

5. The menaquinol compound of the Formula I of claim 1 , wherein

m is 7, 8, 9 or 10;

R 1 is H and R 2 is or the acyl residue of ferulic acid 21; or

R 2 is H and R 1 is the acyl residue of ferulic acid 21;

6. The menaquinol compound of the Formula I of claim 1 , wherein

m is 7, 8, 9 or 10;

R 1 is H and R 2 is the acyl residue of chlorogenic acid 22; or

R 2 is H and R 1 is the acyl residue of chlorogenic acid 22;

7. The menaquinol compound of the Formula I of claim 1 , wherein

m is 7, 8, 9 or 10;

R 1 is H and R 2 is the acyl residue of quinic acid 23; or

R 2 is H and R 1 is the acyl residue of quinic acid 23;

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2020
From: DROUET, KEITH E.; TUMLIN, JAMES A; RUDEY, JOHN M.
To: EPIZON PHARMA, INC.
Reel/Frame 053939/0075 →
Continuity (2)
Provisional Application 62730149 · Sep 12, 2018
Related Publication 20200079718A1 · Mar 12, 2020
Cited By (1)
US 12,433,854